Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Association Of Interleukin-17a And Chemokine/vascular Endothelial Growth Factor-induced Angiogenesis In Newly Diagnosed Patients With Bladder Cancer.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Association Of Interleukin-17a And Chemokine/vascular Endothelial Growth Factor-induced Angiogenesis In Newly Diagnosed Patients With Bladder Cancer.

Related Experiment Video

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Association of interleukin-17A and chemokine/vascular endothelial growth factor-induced angiogenesis in newly diagnosed patients with bladder cancer.

Ali Moadab1, Mohammad Rafie Valizadeh1, Alireza Nazari2,3

  • 1Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.

BMC Immunology
|March 22, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Interleukin-17 (IL-17) pathway genes and proteins like CXCR2, IL-17RA, IL-17RC, IL-17A, VEGF, and TGF-β are dysregulated in bladder cancer (BC). These molecules show potential as diagnostic and therapeutic targets for BC.

Keywords:
Bladder cancerCXCR2IL-17ATGF-β

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.8K

Related Experiment Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.8K

Area of Science:

  • Oncology
  • Immunology

Background:

  • The Interleukin-17 (IL-17) cytokine family and its receptors play complex roles in human malignancies, potentially supporting or inhibiting tumor growth.
  • Understanding the specific roles of IL-17 family members and associated signaling molecules in bladder cancer (BC) is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the expression of CXCR2, IL-17RA, and IL-17RC genes at the mRNA level in bladder cancer patients.
  • To quantify the tissue and serum levels of IL-17A, vascular endothelial growth factor (VEGF), and transforming growth factor β (TGF-β) in bladder cancer patients compared to controls.

Main Methods:

  • Gene expression analysis of CXCR2, IL-17RA, and IL-17RC in tumor and normal tissues.
  • Measurement of serum and tissue concentrations of IL-17A, VEGF, and TGF-β using appropriate assays.
VEGF

Main Results:

  • Significant upregulation of IL-17RA, IL-17RC, and CXCR2 gene expression was observed in bladder cancer tumoral tissues compared to normal tissues.
  • Distinct differences in serum and tissue concentrations of IL-17A, VEGF, and TGF-β were found between bladder cancer patients and the control group, as well as between tumor and normal tissues.

Conclusions:

  • Bladder cancer is associated with significant dysregulation of CXCR2, IL-17RA, and IL-17RC gene expression.
  • Altered levels of IL-17A, VEGF, and TGF-β in bladder cancer patients suggest their involvement in disease development.
  • These findings highlight the potential of targeting the IL-17 pathway, CXCR2, VEGF, and TGF-β for bladder cancer diagnosis and therapy.